1 janv. 1997 - Rituximab
Description:
For use in patients with treatment-resistant, low-grade or follicular B-cell non-Hodgkin lymphoma (NHL), the Food and Drug Administration (FDA) approves rituximab, a monoclonal antibody.
Ajouté au bande de temps:
Date: